Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany.
COVID-19
Germany
Multiple sclerosis
SARS-CoV-2
Journal
Neurological research and practice
ISSN: 2524-3489
Titre abrégé: Neurol Res Pract
Pays: England
ID NLM: 101767802
Informations de publication
Date de publication:
16 Aug 2021
16 Aug 2021
Historique:
received:
05
07
2021
accepted:
15
07
2021
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
18
8
2021
Statut:
epublish
Résumé
Since the coronavirus disease 2019 (COVID-19) has risen, several risk factors have been identified, predicting a worse outcome. It has been speculated that patients with Multiple sclerosis (MS) have an increased risk for a severe course of COVID-19 due to a suspected higher vulnerability. Therefore, we aimed to analyze the impact of comorbid MS on the outcome of patients with COVID-19 in Germany. We conducted a retrospective cross-sectional study using the administrative database of all hospitalized patients diagnosed with PCR-confirmed COVID-19 (n = 157,524) in Germany during 2020. The cohort was stratified according to the presence (n = 551) or absence (n = 156,973) of comorbid MS, including discrimination of MS subtypes. Primary outcome measures were admission to the intensive care unit (ICU), use of invasive or non-invasive ventilation, and in-hospital mortality. Differences were investigated using rates and odds ratios as estimates. Pooled overall estimates, sex-stratified estimates, age-group stratified estimates, and MS subtype stratified estimates were calculated for all outcomes under the random-effects model. Among 157,524 patients hospitalized with COVID-19, 551 had a concurrent MS diagnosis (0.3%). Overall, univariate analysis showed lower rates of ICU admission (17.1% versus 22.7%, p < 0.001), lower use of ventilation (9.8% versus 14.5%, p < 0.001) and lower in-hospital mortality (11.1% versus 19.3%, p < 0.001) among COVID-19 patients with comorbid MS. This finding was stable across the subgroup analysis of sex and MS subtype but was attenuated by age-stratification, confirming equal odds of in-hospital mortality between COVID-19 patients with and without MS (log OR: 0.09 [95% CI: - 0.40, 0.59]). Although there might be differences in risk within the MS patients' population, this large-scale nationwide analysis found no evidence for a worse outcome of COVID-19 in patients with comorbid MS compared to non-MS individuals.
Sections du résumé
BACKGROUND
BACKGROUND
Since the coronavirus disease 2019 (COVID-19) has risen, several risk factors have been identified, predicting a worse outcome. It has been speculated that patients with Multiple sclerosis (MS) have an increased risk for a severe course of COVID-19 due to a suspected higher vulnerability. Therefore, we aimed to analyze the impact of comorbid MS on the outcome of patients with COVID-19 in Germany.
METHODS
METHODS
We conducted a retrospective cross-sectional study using the administrative database of all hospitalized patients diagnosed with PCR-confirmed COVID-19 (n = 157,524) in Germany during 2020. The cohort was stratified according to the presence (n = 551) or absence (n = 156,973) of comorbid MS, including discrimination of MS subtypes. Primary outcome measures were admission to the intensive care unit (ICU), use of invasive or non-invasive ventilation, and in-hospital mortality. Differences were investigated using rates and odds ratios as estimates. Pooled overall estimates, sex-stratified estimates, age-group stratified estimates, and MS subtype stratified estimates were calculated for all outcomes under the random-effects model.
RESULTS
RESULTS
Among 157,524 patients hospitalized with COVID-19, 551 had a concurrent MS diagnosis (0.3%). Overall, univariate analysis showed lower rates of ICU admission (17.1% versus 22.7%, p < 0.001), lower use of ventilation (9.8% versus 14.5%, p < 0.001) and lower in-hospital mortality (11.1% versus 19.3%, p < 0.001) among COVID-19 patients with comorbid MS. This finding was stable across the subgroup analysis of sex and MS subtype but was attenuated by age-stratification, confirming equal odds of in-hospital mortality between COVID-19 patients with and without MS (log OR: 0.09 [95% CI: - 0.40, 0.59]).
CONCLUSIONS
CONCLUSIONS
Although there might be differences in risk within the MS patients' population, this large-scale nationwide analysis found no evidence for a worse outcome of COVID-19 in patients with comorbid MS compared to non-MS individuals.
Identifiants
pubmed: 34399858
doi: 10.1186/s42466-021-00143-y
pii: 10.1186/s42466-021-00143-y
pmc: PMC8364944
doi:
Types de publication
Journal Article
Langues
eng
Pagination
42Informations de copyright
© 2021. The Author(s).
Références
Ther Adv Neurol Disord. 2021 Jul 7;14:17562864211030656
pubmed: 34285719
JAMA Neurol. 2020 Sep 1;77(9):1079-1088
pubmed: 32589189
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
Neurol Res Pract. 2020;2(1):22
pubmed: 32835166
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
BMJ. 2020 Nov 27;371:m4509
pubmed: 33246972
Nature. 2020 Sep;585(7823):16-17
pubmed: 32860026
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Nat Rev Drug Discov. 2019 Dec;18(12):905-922
pubmed: 31399729
Immunol Rev. 2014 May;259(1):231-44
pubmed: 24712469
Neuron. 2006 Oct 5;52(1):61-76
pubmed: 17015227
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Mult Scler. 2020 Sep;26(10):1157-1162
pubmed: 32662757
Neurol Res Pract. 2020 Nov 19;2:48
pubmed: 33230500
JAMA Neurol. 2021 Jun 1;78(6):699-708
pubmed: 33739362
Neurol Neuroimmunol Neuroinflamm. 2020 Jul 9;7(5):
pubmed: 32646885